Already at 20% enrollment, 2 week trial. That should go very fast and support the phase 2b/3 trial for severe indications. My guess is the phase 2b/3 has 390 patients compared to this phase 2 with 75 patients, because they might go straight to approval in the severe poplulation with results in that trial and not require another phase 3 trial.